☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
abbvie
AbbVie’s Elahere (Mirvetuximab Soravtansine) Receives the EC’s Approval to Treat Platinum-Resistant Ovarian Cancer
November 18, 2024
AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia
November 12, 2024
AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology
November 4, 2024
AbbVie to Acquire Aliada Therapeutics for ~$1.4B
November 26, 2024
AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions
October 25, 2024
AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the J...
October 21, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.